{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-25-000023","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.450678+00:00","generated_at":"2026-05-26T01:20:17.010456+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M","bullets":["Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.","Exclusive global license with Vanda for imsidolimab: $15M upfront, up to $35M milestones, 10% royalty on net sales.","Cash and investments $420.8M at Dec 31, 2024; cash runway reiterated through year-end 2027.","Collaboration revenue from GSK Jemperli milestones $43.1M in Q4 and $91.3M in FY2024; Jemperli 2024 sales $598M (>200% growth).","Net loss $21.8M in Q4 ($0.72 loss per share) vs $42.2M in prior year; FY2024 net loss $145.2M ($5.12 per share)."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-25-000023","json":"https://secwatch.observer/filing/0001370053-25-000023.json","markdown":"https://secwatch.observer/filing/0001370053-25-000023.md","text":"https://secwatch.observer/filing/0001370053-25-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/0001370053-25-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005325000023/anab-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:20:17.010456+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}